RADx® Tech and ATP Programs

word cloud with stats on RADx Tech program

The RADx® Tech/ATP programs are components of the overarching RADx Initiative at NIH to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The RADx Tech/ATP innovation funnel was designed to compress the customary technology development timeline from years down to just months.  This was accomplished by employing, in parallel, expert teams to address technical, regulatory, clinical, and commercialization requirements. Launched on April 29, 2020, the RADx programs were able to validate, de-risk, scale up, manufacture, and deploy novel tests through a seamless pipeline by fall 2020. 

These programs have increased testing capacity in the U.S. by billions. As the COVID-19 pandemic evolves, NIBIB continues to support projects to fill unmet needs in diagnostic testing. 

Funding Opportunity

illustration of sars-cov-2 virus and double helix with the title funding opportunity written on top of image

RADX Tech Solicitations

NIBIB's RADx Tech program has issued two new funding opportunities for diagnostic test manufacturers to develop COVID-19 tests that are accessible to people with disabilities and tests with improved performance. See links below for details on each solicitation. Applications will be accepted on a rolling basis starting on September 20, 2022.

 

generic bar chart titled tests produced

Program Dashboard

Summary data on proposals submitted to the RADx Tech and ATP Programs.

  • 4 billion tests and test products produced 
  • 46 FDA authorizations
  • 1st over-the-counter test for use at home
  • >100 companies supported
photo of women using nasal swab

Authorized Tests

List of RADx Tech/ATP supported lab, point-of-care, and over-the-counter/at-home tests and test products that have received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).  

RADx Testing

Tests in Development

Descriptions of innovative point of care, home-based, improved clinical laboratory tests, and testing products that are increasing the capacity of testing in the U.S.

RADx Tech organization chart

Partners

The RADx Tech and ATP programs leverage the Point of Care Technology Research Network and joined with numerous other federal agencies, offices, NIH institutes, and contractors.

timeline starting at 2020 with milestones

RADx® Tech Timeline

See the milestones and success that have unfolded since the beginning of the RADx Tech program.

Learn more about this accelerated pathway designed to help bring to market over the counter diagnostic tests for COVID-19 that are not yet authorized by the FDA.

Learn about this effort to securely send results from a self-administered test to public health systems. The process is designed to work with different tests and includes an option for anonymous reporting. 

RADx Tech, along with its collaborators, is working on an effort to develop at-home diagnostic tests for COVID-19 that can be used independently by people with disabilities. The initial focus is with people who are blind or have low vision, people with fine motor difficulties, and home tests for older adults. 

When to Test tool now has an individual calculator to help guide individuals and families on COVID-19 testing. The Testing Impact Calculator also includes tools to help organizations plan for and develop testing strategies, and playbooks for pooled testing and K-12 schools. This site includes other resources on testing strategies and obtaining supplies. Try the calculator.

The Say Yes COVID Test project is a cooperative effort from state and local health departments, NIH, and CDC.  This program offers access to free, rapid, at-home COVID-19 testing in select communities throughout the U.S. Learn more.  

Information about studies to evaluate diagnostic tests being developed for COVID-19.

This webinar series hosted by POCTRN provides information on RADx® Tech/ATP program activities.  Register for upcoming events or watch previous webinars.

Videos

View videos about RADx Tech/ATP programs, interviews with the NIBIB Director and more.

Program Contacts

Program Contacts

Current grantees contact Program Director on your existing award.

RADx® Tech programmatic or technical inquiries: info.radx@poctrn.org

All other RADx® Tech Applicants: RADxNIBIB@mail.nih.gov

SBIR/STTR Applicants: NIBIB-SBIR@mail.nih.gov

All others: COVID19Grants@nih.gov

Related Resources

Related News

September 15, 2022
Illustration of SARS-CoV-2 viral particles in different colors on a blue background
A research team funded by the National Institutes of Health has shown that commercially available rapid antigen tests can detect past and present variants of concern and has identified potential mutations that may impact test performance in the future.
September 8, 2022
coronavirus particle with dna overlay and text funding announcement
NIH has issued two new funding opportunities for diagnostic test manufacturers to develop the next generation of COVID-19 diagnostics.
August 26, 2022
Girl uses nasal swab to collect a sample for a COVID-19 test.
A new study that could have immediate implications for COVID-19 testing in schools found that with age-appropriate instructions, school-aged children can successfully use a nasal swab to obtain their own COVID-19 test specimen.
June 30, 2022
The Council on Strategic Risks hosted a webinar on June 8 titled RADx® Initiative & COVID-19 Solutions: Bioengineering at Unprecedented Speed and Scale. This NIH RADx Initiative was critical in the shift from solely laboratory-based testing to the public-private partnership that enabled the production and accessibility of point-of-care and over-the-counter COVID-19 tests. Source: Council on Strategic Risks
June 29, 2022
3D rendering of SARS-CoV-2
Researchers funded by NIH's RADx Tech program have developed a fast, cost-effective method to detect the circulation of SARS-CoV-2 variants. The team adopted a customizable genotyping approach to identify known variants and subvariants—an approach that can augment current surveillance.